Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06773936 | Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia | PHASE2 | ENROLLING BY_INVITATION | 55 | — | — | May 15, 2026 | Jul 1, 2033 | May 6, 2026 | 8 | United States |
Major molecular remission (MMR), also known as MR3.0, is defined as BCR-ABL transcript levels (expressed as a percentage compared with the ABL control gene) ≤ 0.1% based on PCR at day 85.
| Name | Type | Description |
|---|---|---|
| Induction Phase | DRUG | Asciminib, Dasatinib, Prednisone, and Methotrexate |
| Re-Induction Phase | DRUG | Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone |
| Post-Remission | DRUG | Blinatumomab, Dasatinib, Methotrexate and Dexamethasone |
| Maintenance | DRUG | Asciminib, Dasatinib, Prednisone, and Methotrexate |
Inclusion Criteria: * Participants must have a new diagnosis of Philadelphia chromosome positive (Ph+) ALL by cytogenetics, FISH, or polymerase chain reaction (PCR). Diagnostic specimens must be submitted to the site's local CLIA-approved cytogenetics laboratory and results (cytogenetics, FISH, or ...